JP2016510749A - キナゾリノン抗生物質 - Google Patents

キナゾリノン抗生物質 Download PDF

Info

Publication number
JP2016510749A
JP2016510749A JP2015561621A JP2015561621A JP2016510749A JP 2016510749 A JP2016510749 A JP 2016510749A JP 2015561621 A JP2015561621 A JP 2015561621A JP 2015561621 A JP2015561621 A JP 2015561621A JP 2016510749 A JP2016510749 A JP 2016510749A
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
compound according
pbp2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2015561621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016510749A5 (enExample
Inventor
メイランド チャン，
メイランド チャン，
シャリアー モバシェリー，
シャリアー モバシェリー，
レニー ボウリー，
レニー ボウリー，
Original Assignee
ユニヴァーシティー オブ ノートル ダム デュ ラック
ユニヴァーシティー オブ ノートル ダム デュ ラック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ノートル ダム デュ ラック, ユニヴァーシティー オブ ノートル ダム デュ ラック filed Critical ユニヴァーシティー オブ ノートル ダム デュ ラック
Publication of JP2016510749A publication Critical patent/JP2016510749A/ja
Publication of JP2016510749A5 publication Critical patent/JP2016510749A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015561621A 2013-03-05 2014-03-05 キナゾリノン抗生物質 Ceased JP2016510749A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361851310P 2013-03-05 2013-03-05
US61/851,310 2013-03-05
PCT/US2014/020910 WO2014138302A1 (en) 2013-03-05 2014-03-05 Quinazolinone antibiotics

Publications (2)

Publication Number Publication Date
JP2016510749A true JP2016510749A (ja) 2016-04-11
JP2016510749A5 JP2016510749A5 (enExample) 2017-04-06

Family

ID=51491923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015561621A Ceased JP2016510749A (ja) 2013-03-05 2014-03-05 キナゾリノン抗生物質

Country Status (4)

Country Link
US (2) US9776975B2 (enExample)
EP (1) EP2964618B1 (enExample)
JP (1) JP2016510749A (enExample)
WO (1) WO2014138302A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111434775B (zh) * 2019-01-11 2022-12-06 上海医药工业研究院 一种发酵制备达托霉素的方法
CN110437162B (zh) * 2019-07-09 2021-01-05 贵州医科大学 一种含环羟肟酸的化合物及其制备方法和应用
US11648248B1 (en) 2022-01-12 2023-05-16 King Abdulaziz University Potent antimicrobial compounds with a pyridazine nucleus
EP4722198A1 (en) * 2024-10-04 2026-04-08 Technische Universität München, in Vertretung des Freistaats Bayern Compounds for use in the treatment of bacterial diseases and infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01110677A (ja) * 1987-10-23 1989-04-27 Asahi Chem Ind Co Ltd 新規キナゾリノン化合物およびその製造方法
JP2009514954A (ja) * 2005-11-04 2009-04-09 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能を変調するための化合物
US20100004324A1 (en) * 2008-06-25 2010-01-07 Eric Skaar Antimicrobial compounds and methods of use thereof
WO2012135416A1 (en) * 2011-03-29 2012-10-04 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
GB0412769D0 (en) * 2004-06-08 2004-07-07 Novartis Ag Organic compounds
US9045442B2 (en) 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
WO2009137677A2 (en) * 2008-05-07 2009-11-12 Innovative Biosensors, Inc. Reagents, methods, and systems for detecting methicillin-resistant staphylococcus
US20100197650A1 (en) 2008-08-28 2010-08-05 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising ceftaroline

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01110677A (ja) * 1987-10-23 1989-04-27 Asahi Chem Ind Co Ltd 新規キナゾリノン化合物およびその製造方法
JP2009514954A (ja) * 2005-11-04 2009-04-09 ハイドラ バイオサイエンシズ インコーポレイテッド Ｔｒｐｖ３機能を変調するための化合物
US20100004324A1 (en) * 2008-06-25 2010-01-07 Eric Skaar Antimicrobial compounds and methods of use thereof
WO2012135416A1 (en) * 2011-03-29 2012-10-04 Trana Discovery, Inc. Screening methods for identifying specific staphylococcus aureus inhibitors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOLOGIA, BRATISLAVA, vol. 59(6), JPN6018006532, 2004, pages 741 - 752, ISSN: 0003746146 *
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 65(3), JPN6018006530, 2003, pages 268 - 273, ISSN: 0003746148 *
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 69(3), JPN6018006529, 2007, pages 476 - 478, ISSN: 0003746147 *
REGISTRY(STN)[ONLINE], JPN7018000551, ISSN: 0003746143 *
REGISTRY(STN)[ONLINE], JPN7018000552, ISSN: 0003746144 *
REGISTRY(STN)[ONLINE], JPN7018000553, ISSN: 0003746145 *

Also Published As

Publication number Publication date
EP2964618A4 (en) 2016-08-03
US9776975B2 (en) 2017-10-03
US20180029997A1 (en) 2018-02-01
US20160031832A1 (en) 2016-02-04
US10329262B2 (en) 2019-06-25
EP2964618A1 (en) 2016-01-13
EP2964618B1 (en) 2019-09-04
WO2014138302A1 (en) 2014-09-12

Similar Documents

Publication Publication Date Title
US11339136B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP6863970B2 (ja) ヘテロ環式化合物およびそれらの使用
CN108463459A (zh) 非β-内酰胺类抗生素
US9302012B2 (en) Anti-bacterial siderophore-aminopenicillin conjugates
US20210261516A1 (en) Myc g-quadruplex stabilizing small molecules and their use
WO2020037092A1 (en) Imidazo[4,5-c]quinoline derived nlrp3-modulators
US10329262B2 (en) Quinazolinone antibiotics
WO2018177218A1 (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
JP7357934B2 (ja) ベンズアミド抗菌剤
CN106957315B (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
US11149046B2 (en) Antibacterial sideromycins
AU2002314773B2 (en) Peptide deformylase activated prodrugs
US12502362B2 (en) Inhibitors of nucleotidyltransferase superfamily enzymes as antibiotics
US9862680B2 (en) Peripherally substituted monocyclic beta-lactams
JP2017538675A (ja) 微生物感染を治療するための相乗的組成物
CN110981888B (zh) N-芳基二硫吡咯酮脲类和氨基酯类衍生物及其制备和应用
US10472326B2 (en) PQSR modulators
CN103483315A (zh) 7-（3-氨甲基-4-烷氧亚胺基-1-吡咯烷基）-1-[(1r,2s)-2-氟环丙基]喹诺酮羧酸类化合物及其制备方法
US20180021277A1 (en) Anti-virulence compositions and methods
Zaidi et al. Synthesis of novel 2-(4-ALLYLPIPERAZIN-1-YL)-1-(1-ARYL-1H-TETRAZOL-5-YL) ethanone derivatives as potential antimicrobial agents
JP2017105714A (ja) 多剤排出ポンプ阻害剤
CN104892600B (zh) 7‑（3‑氨甲基‑4‑取代苄氧亚胺基‑1‑吡咯烷基）萘啶酮羧酸类化合物
JP2014503578A (ja) Ｍｄｒポンプ阻害活性を有する新規なアザクマリン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170303

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180528

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180626

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20181030